Searching for a New Indication

Tibin K. Titus, Mercer University College of Pharmacy

Hypertension is a worldwide problem with its prevalence increasing in the aging population. Complications of hypertension include stroke and cardiovascular diseases. [1] Angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), diuretics, and calcium channel blockers are recommended as first line therapy. [2]

Sacubitril/valsartan (Entresto®) is a combination product consisting of an angiotensin receptor neprilysin inhibitor, sacubitril, and an ARB, valsartan. [3] Previous studies with sacubitril/valsartan have demonstrated significant reductions in office and ambulatory BP compared with valsartan or placebo. [4]

Continue reading


Weight Loss, is it Worth the Cost?

Meron Mezgebe, Mercer University College of Pharmacy

The estimated global incidence of diabetes is predicted to increase to 439 million adults by 2030 partially due to increasing prevalence of obesity and sedentary lifestyle. Diabetes may lead to premature death and complications such as blindness, amputations, renal disease, and cardiovascular diseases. [1] In the U.S., Type 2 Diabetes (T2D) costs the economy over $245 billion yearly. [2] Gastric band (GB) surgery for obese people with T2D was previously found to be cost-effective and clinically effective compared with non-surgical interventions. [3]

Continue reading